The setting could not have been less threatening. I was sitting in the press room on the last day of the Alzheimer’s Association International…
Reporter Phil Gutis reflects his experience at AAIC — and on the barriers between lay people and scientists when it comes to the latest…
At AAIC, reporter Phil Gutis learns low-intensity exercise could stop mild cognitive impairment in its tracks. But, researchers say, knowing this is only half…
“She no longer remembered who I was, but our lifelong connection through LEGO bricks kept our communication and engagement alive.” –Loretta Veney Loretta Veney…
Writer and news reporter Phil Gutis brings his keen nose for news — and his experience living with early-onset Alzheimer’s — to the halls…
At this year’s AAIC, the developer of an Alzheimer’s blood test debuts promising data, while the Alzheimer’s Association warns new blood-based biomarkers aren’t quite…
In the midst of a media frenzy around fraud allegations and a key Alzheimer’s drug target, reporter Phil Gutis reflects on his personal experience…
A few weeks ago, my husband Tim and I were sitting at our kitchen counter, chatting over dinner and looking through the day’s mail….
Image: Phil Gutis receives an aducanumab infusion while carrying out his “silly shoe challenge.” Phil Gutis reflects on the significance of participating in the…
“It’s Time for More Time” With the #MoreTime campaign, the Alzheimer’s Association has gone all in on aducanumab, the controversial new Alzheimer’s drug produced…
A few months ago, we discovered some disturbingly large and firm lumps on our dog Sadie. We quickly made an appointment with the vet…
Jason Karlawish is disappointed. Angry even. Read his new book The Problem of Alzheimer’s: How Science, Culture and Politics Turned a Rare Disease Into…
Wall Street traders seem to have gained a new favorite potential Alzheimer’s treatment as shares of Cassava Science, a small and virtually unknown company,…
Biogen’s Alzheimer’s drug aducanumab encounters another bump in the road as the FDA delays its approval decision. The Federal Drug Administration has given itself…
In a surprising turn of events, the Advisory Committee of experts on Biogen’s experimental Alzheimer’s drug aducanumab recommended against FDA approval of the drug…